Premium
Long‐term outcome of expanded newborn screening at Boston children's hospital: benefits and challenges in defining true disease
Author(s) -
Landau Yuval E.,
Waisbren Susan E.,
Chan Lawrence M. A.,
Levy Harvey L.
Publication year - 2017
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1007/s10545-016-0004-4
Subject(s) - biotinidase deficiency , newborn screening , pediatrics , disease , medicine
There is no universal consensus of the disorders included in newborn screening programs. Few studies so far, mostly short‐term, have compared the outcome of disorders detected by expanded newborn screening (ENBS) to the outcome of the same disorders detected clinically. Methods We compared the clinical and neurodevelopmental outcomes in patients with metabolic disorders detected by ENBS, including biotinidase testing, with those detected clinically and followed at the Metabolism Clinic at Boston Children's Hospital. Results One hundred eighty‐nine patients came to attention from ENBS and 142 were clinically diagnosed. 3‐methylcrotonyl‐CoA carboxylase, biotinidase, and carnitine deficiencies were exclusively identified by ENBS and medium chain acyl‐CoA dehydrogenase (MCADD) and very long chain acyl‐CoA dehydrogenase deficiencies (VLCADD) were predominantly identified by ENBS whereas the organic acid disorders more often came to attention clinically. Only 2% of the ENBS‐detected cases had clinically severe outcomes compared to 42% of those clinically detected. The mean IQ score was 103 + 17 for the ENBS‐detected cases and 77 + 24 for those clinically detected. Those newly included disorders that seem to derive the greatest benefit from ENBS include the fatty acid oxidation disorders, profound biotinidase deficiency, tyrosinemia type 1, and perhaps carnitine deficiency. Conclusion Although the NBS‐identified and clinically‐identified cohorts were not completely comparable, this long‐term study shows likely substantial improvement overall in the outcome of these metabolic disorders in the NBS infants. Infants with mild disorders and benign variants may represent a significant number of infants identified by ENBS. The future challenge will be to unequivocally differentiate the disorders most benefitting from ENBS and adjust programs accordingly.